Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis.
Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...